Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-07-25, Stock:ABBV, The news for the past five days is as follows:
2018-07-18: NEWS1: Drugmakers Game the Patent System and Reap Billions, FDA Says.NEWS2: FDA Blasts Drugmakers Thwarting Competition on Costly Biologics.NEWS3: AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S..NEWS4: AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S..NEWS5: AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S..NEWS6: What's Behind Johnson & Johnson's Double-Digit Growth?.NEWS7: What's Behind Johnson & Johnson's Double-Digit Growth?.
2018-07-19: NEWS1: Why AbbVie Shares Are Sliding Today.NEWS2: Why AbbVie Shares Are Sliding Today.NEWS3: AbbVie Has Issues, But It Isn't the 'Next Big Drug Short'.NEWS4: Notable Thursday Option Activity: ABBV, HSY, AVB.NEWS5: Notable Thursday Option Activity: ABBV, HSY, AVB.NEWS6: Why AbbVie Shares Are Sliding Today.NEWS7: 3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola.NEWS8: 3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola.NEWS9: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS10: Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?.NEWS11: Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?.NEWS12: Biogen (BIIB) to Report Q2 Earnings: What's in the Cards?.NEWS13: How AbbVie Makes its Money.NEWS14: AbbVie's Tumble May Not Last.NEWS15: AbbVie's Stock Hit By Citron Tweet.NEWS16: 3 Biotech Stocks to Watch This Quarter.NEWS17: AbbVie shares drop 5.5% after short seller Citron calls it &apos;next great drug short&apos;.NEWS18: Biogen (BIIB) to Report Q2 Earnings: What&apos;s in the Cards?.NEWS19: 3 Big Stock Charts for Thursday: McDonald’s, AbbVie and Coca-Cola.
2018-07-20: NEWS1: Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?.NEWS2: Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?.NEWS3: Analysts’ Recommendations for Stryker and Its Peers in July.NEWS4: Will HIV Sales Drive Gilead (GILD) to Beat in Q2 Earnings?.NEWS5: AbbVie Becomes Oversold (ABBV).NEWS6: AbbVie Becomes Oversold (ABBV).NEWS7: Analyzing AbbVie before Its Second-Quarter Earnings.NEWS8: Pharma Stock Roundup: JNJ & NVS&apos; Q2 Earnings, FDA Approvals.NEWS9: 3 Top Healthcare Stocks to Buy in July.NEWS10: 3 Top Healthcare Stocks to Buy in July.NEWS11: Today’s Research Reports on Stocks to Watch: eBay and AbbVie.NEWS12: 3 Top Healthcare Stocks to Buy in July.
2018-07-23: NEWS1: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS2: With new attack on Alzheimer&apos;s, this young biotech is hiring, grabbing more space.NEWS3: Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?.NEWS4: Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?.NEWS5: Healthcare ETFs to Buy on Solid Q2 Earnings Expectations.NEWS6: Healthcare ETFs to Buy on Solid Q2 Earnings Expectations.NEWS7: Healthcare ETFs to Buy on Solid Q2 Earnings Expectations.NEWS8: Better Buy: Gilead Sciences, Inc. vs. Celgene.NEWS9: Better Buy: Gilead Sciences, Inc. vs. Celgene.NEWS10: AbbVie's Stock Is a Bargain After Falling 8% Last Week.NEWS11: AbbVie's Stock Is a Bargain After Falling 8% Last Week.NEWS12: Better Buy: Gilead Sciences, Inc. vs. Celgene.NEWS13: How Johnson & Johnson’s Earnings Trended in Q2 2018.NEWS14: AbbVie&apos;s Stock Is a Bargain After Falling 8% Last Week.
2018-07-24: NEWS1: Citron's Left reiterates belief AbbVie shares will fall sharply.NEWS2: AbbVie prices new endometriosis drug at $10,000 a year.NEWS3: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS4: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS5: Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?.NEWS6: Merck (MRK) Q2 Earnings Coming Up: What's in the Cards?.NEWS7: Merck (MRK) Q2 Earnings Coming Up: What&apos;s in the Cards?.NEWS8: AbbVie Wins U.S. Approval for Endometriosis Pain Treatment.NEWS9: AbbVie Gets Approval for Endometriosis Pain Treatment.NEWS10: AbbVie Gets OK for Potential Blockbuster Endometriosis Treatment.NEWS11: Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?.NEWS12: What's in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS13: What's in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS14: AbbVie wins FDA approval for oral treatment for endometriosis pain.NEWS15: Eli Lilly Surpasses Estimates, Reports Growth in Q2 2018.NEWS16: AbbVie Receives U.S. FDA Approval of ORILISSA™ (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis.NEWS17: What to Expect When AbbVie Reports Q2 Earnings.NEWS18: What to Expect When AbbVie Reports Q2 Earnings.NEWS19: What&apos;s in Store for Cardinal Health (CAH) in Q4 Earnings?.NEWS20: J&J’s Oncology Franchise Saw 42.2% Growth in Q2 2018.NEWS21: What to Expect When AbbVie Reports Q2 Earnings.NEWS22: Validea John Neff Strategy Daily Upgrade Report - 7/24/2018.NEWS23: Validea John Neff Strategy Daily Upgrade Report - 7/24/2018.NEWS24: AbbVie Reports FDA Approval Of ORILISSA - Quick Facts.NEWS25: AbbVie Reports FDA Approval Of ORILISSA - Quick Facts.NEWS26: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS27: What’s Next for Pfizer Stock After Being Called Out by President Trump.NEWS28: Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?.NEWS29: Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?.

Answer: Rise